Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-23-007956
Filing Date
2023-03-15
Accepted
2023-03-15 07:43:00
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2022defa14ainternet.htm DEFA14A 38755
2 GRAPHIC image_10.jpg GRAPHIC 53670
3 GRAPHIC image_11.jpg GRAPHIC 1318
4 GRAPHIC image_13.jpg GRAPHIC 10207
  Complete submission text file 0001628280-23-007956.txt   129915
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33637 | Film No.: 23733302
SIC: 2834 Pharmaceutical Preparations